Trump Vows 59% Cut to Drug Prices, Sends Shockwaves Through Pharma Stocks
U.S. President Donald Trump has reignited his push to slash prescription drug prices, declaring on Monday that “DRUG PRICES TO BE CUT BY 59%,” in a bold post from his social media platform.
The statement, which also promised lower costs for gasoline, energy, groceries, and “NO INFLATION,” sent ripples through the pharmaceutical sector, with U.S. drugmaker shares dropping 2–3% in early trading.
While the president provided no specific policy details, the announcement comes ahead of a scheduled health-focused event at the White House. Trump also reiterated his intention to pursue a long-touted executive order that would implement “most favored nation” pricing—linking U.S. drug costs to those in countries where medicines are sold more cheaply. A similar attempt in his first term was blocked by the courts, but the renewed push suggests Trump is preparing to make drug affordability a cornerstone of his economic and healthcare agenda.
Pharmaceutical stocks around the globe, already jittery from weekend remarks, slid further following Monday’s post. The lack of clarity around implementation has stirred both political and market speculation.
The broader implications are notable: if Trump is successful in enacting such pricing reforms, it could have sweeping consequences for pharmaceutical companies’ profit margins, research pipelines, and pricing strategies worldwide.
As investors await further information during the upcoming White House event, markets are likely to remain volatile across both health and energy sectors.
Kosta Gushterov
Reporter at Coindoo
Kosta has been a part of the team since 2021 and has solidified his position with a thirst for knowledge, incredible dedication to his work and a “detective-like” mindset. He not only covers a wide range of trending topics, he also creates reviews, PR articles and educational content. His work has also been referenced by other news outlets.
